SCHEDULE: Intracoastal Capital Discloses 9.1% Stake in Phio Pharma

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.1% beneficial ownership stake in Phio Pharmaceuticals Corp. as of December 31, 2025.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Phio Pharmaceuticals Corp.
• As of December 31, 2025, the Reporting Persons beneficially own an aggregate of 1,142,556 shares of Phio Pharmaceuticals Corp. common stock.
• This ownership represents approximately 9.1% of the company's common stock, calculated based on 11,447,952 shares outstanding as of December 4, 2025, plus the 1,142,556 shares issuable upon warrant exercise.
• The beneficially owned shares are issuable upon the exercise of "Intracoastal Warrant 1" held by Intracoastal Capital LLC.
• Two other warrants, "Intracoastal Warrant 2" (149,298 shares) and "Intracoastal Warrant 3" (759,298 shares), are excluded from this calculation due to blocker provisions that prevent exercise if it would result in beneficial ownership exceeding 4.99%.
• Without these blocker provisions, the Reporting Persons would have been deemed to beneficially own 2,051,152 shares of common stock.
• The Reporting Persons hold shared voting and dispositive power over the 1,142,556 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor group is maintaining a substantial stake, suggesting continued confidence in Phio Pharmaceuticals Corp. without indicating an intent to influence control.

Positives

• A significant institutional investor group, Intracoastal Capital LLC, along with key individuals, has maintained a substantial 9.1% stake in Phio Pharmaceuticals Corp., indicating continued interest.
• The disclosure clarifies the beneficial ownership structure, providing transparency to the market regarding a major shareholder.

Negatives

• The presence of blocker provisions on additional warrants suggests a strategic limitation on immediate full exercise, potentially to avoid triggering certain ownership thresholds or regulatory requirements.

Risks

• The value of the beneficial ownership is tied to the performance of Phio Pharmaceuticals Corp.'s common stock, which is subject to market fluctuations and company-specific risks.
• The exercise of warrants could lead to dilution for existing shareholders, although the current filing only reports shares issuable upon exercise of one warrant.

Future Outlook

The filing does not contain forward-looking statements or guidance from Phio Pharmaceuticals Corp. or the reporting persons regarding the company's future performance or strategic direction, beyond the certification that the securities were not acquired for the purpose of changing or influencing control.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive investors holding more than 5% of a company's stock. This filing indicates a continued significant stake by Intracoastal Capital LLC in Phio Pharmaceuticals Corp., a biotechnology company. Such disclosures are important for market transparency, allowing investors to track major shareholder positions, which can sometimes signal confidence or strategic interest in the company's sector, particularly in the often volatile biotech industry.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional holder's stake, which can influence market perception and potentially provide a degree of stability or confidence. The potential for future warrant exercise could lead to dilution, but this is not an immediate event.

Key Dates

Recommendation

The filing indicates a significant, passive ownership stake by an institutional investor group. While this suggests a degree of confidence, it does not provide new operational or financial information about Phio Pharmaceuticals Corp. that would warrant a change in investment thesis. The 9.1% stake is a notable position, but without further context on the company's performance or strategic direction, a 'hold' recommendation is appropriate for seasoned investors to maintain their current position while awaiting more comprehensive updates.

Keywords

Phio Pharmaceuticals Corp., Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Equity Stake